These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 22895139)

  • 1. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
    Maemondo M; Minegishi Y; Inoue A; Kobayashi K; Harada M; Okinaga S; Morikawa N; Oizumi S; Tanaka T; Isobe H; Kudoh S; Hagiwara K; Nukiwa T; Gemma A
    J Thorac Oncol; 2012 Sep; 7(9):1417-22. PubMed ID: 22895139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.
    Inoue A; Suzuki T; Fukuhara T; Maemondo M; Kimura Y; Morikawa N; Watanabe H; Saijo Y; Nukiwa T
    J Clin Oncol; 2006 Jul; 24(21):3340-6. PubMed ID: 16785471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
    Huang SF; Liu HP; Li LH; Ku YC; Fu YN; Tsai HY; Chen YT; Lin YF; Chang WC; Kuo HP; Wu YC; Chen YR; Tsai SF
    Clin Cancer Res; 2004 Dec; 10(24):8195-203. PubMed ID: 15623594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp.
    Sutani A; Nagai Y; Udagawa K; Uchida Y; Koyama N; Murayama Y; Tanaka T; Miyazawa H; Nagata M; Kanazawa M; Hagiwara K; Kobayashi K
    Br J Cancer; 2006 Dec; 95(11):1483-9. PubMed ID: 17106442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer.
    Fujiwara Y; Kiura K; Toyooka S; Takigawa N; Tokumo M; Hotta K; Aoe M; Tabata M; Matsuo K; Date H; Tanimoto M
    Lung Cancer; 2006 Apr; 52(1):99-103. PubMed ID: 16503086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.
    Kimura H; Fujiwara Y; Sone T; Kunitoh H; Tamura T; Kasahara K; Nishio K
    Br J Cancer; 2006 Nov; 95(10):1390-5. PubMed ID: 17060940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports.
    Shukuya T; Takahashi T; Kaira R; Ono A; Nakamura Y; Tsuya A; Kenmotsu H; Naito T; Kaira K; Murakami H; Endo M; Takahashi K; Yamamoto N
    Cancer Sci; 2011 May; 102(5):1032-7. PubMed ID: 21272159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
    Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
    Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
    Kris MG; Natale RB; Herbst RS; Lynch TJ; Prager D; Belani CP; Schiller JH; Kelly K; Spiridonidis H; Sandler A; Albain KS; Cella D; Wolf MK; Averbuch SD; Ochs JJ; Kay AC
    JAMA; 2003 Oct; 290(16):2149-58. PubMed ID: 14570950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of gefitinib on advanced non-small cell lung cancer in expanded access program (EAP)].
    Zhang Y; Zhang L; Xu F; Wang ZQ; Zhao HY; Guan ZZ; Xu GC; Pan ZK
    Ai Zheng; 2006 Dec; 25(12):1561-4. PubMed ID: 17166387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gefitinib treatment for non-small cell lung cancer -- a study including patients with poor performance status.
    Su WP; Yang CH; Yu CJ; Shih JY; Hsu C; Yang PC
    J Formos Med Assoc; 2005 Aug; 104(8):557-62. PubMed ID: 16193176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer.
    Zhang XT; Li LY; Mu XL; Cui QC; Chang XY; Song W; Wang SL; Wang MZ; Zhong W; Zhang L
    Ann Oncol; 2005 Aug; 16(8):1334-42. PubMed ID: 15956035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.
    Asahina H; Yamazaki K; Kinoshita I; Sukoh N; Harada M; Yokouchi H; Ishida T; Ogura S; Kojima T; Okamoto Y; Fujita Y; Dosaka-Akita H; Isobe H; Nishimura M
    Br J Cancer; 2006 Oct; 95(8):998-1004. PubMed ID: 17047648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of gefitinib on Chinese patients with locally advanced or metastatic non-small cell lung cancer: a clinical trial].
    Guan ZZ; Zhang L; Li LY; Jiang GL; Liu XY; Chu DT; Zhao HY; Li W
    Ai Zheng; 2005 Aug; 24(8):980-4. PubMed ID: 16086877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania.
    Veronese ML; Algazy K; Bearn L; Eaby B; Alavi J; Evans T; Stevenson JP; Shults J
    Cancer Invest; 2005; 23(4):296-302. PubMed ID: 16100941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer.
    Reck M; Buchholz E; Romer KS; Krutzfeldt K; Gatzemeier U; Manegold C
    Clin Lung Cancer; 2006 May; 7(6):406-11. PubMed ID: 16800967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Gefitinib in the treatment of advanced non-small cell lung cancer].
    Yang L; Liu XY; Fang J; An TT; Wu MN
    Zhonghua Zhong Liu Za Zhi; 2006 Jun; 28(6):474-7. PubMed ID: 17152500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.
    Taron M; Ichinose Y; Rosell R; Mok T; Massuti B; Zamora L; Mate JL; Manegold C; Ono M; Queralt C; Jahan T; Sanchez JJ; Sanchez-Ronco M; Hsue V; Jablons D; Sanchez JM; Moran T
    Clin Cancer Res; 2005 Aug; 11(16):5878-85. PubMed ID: 16115929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer.
    Lin WC; Chiu CH; Liou JL; Chen YM; Perng RP; Tsai CM
    Lung Cancer; 2006 Nov; 54(2):193-9. PubMed ID: 16996166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.